Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TEM News 8 October 2025 - 6 December 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Updated: December 6, 2025 Tempus AI Inc. (NASDAQ: TEM) has quickly become one of the most closely watched artificial intelligence stocks in healthcare. After a year marked by multiple FDA clearances, strong revenue growth and high-profile partnerships, Wall Street is now debating whether the current share price in the mid‑$70s still leaves meaningful upside. Business Wire+1 Fresh research notes and news items published on December 5–6, 2025—including new institutional buying, updated growth forecasts and a cluster of analyst price targets—are reshaping the conversation around the stock’s outlook heading into 2026. MarketBeat+2Nasdaq+2 Tempus AI at a glance Tempus AI is a
6 December 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum accelerated in 2025 as the company delivered strong results and AI breakthroughs. By early September 2025, TEM had more than doubled its IPO price, reaching the high-$80s to $90 range ts2.tech. A series of catalysts (detailed below) then propelled the
9 October 2025
·
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Company Overview and Mission Tempus AI, Inc. is an American health technology company founded in 2015 by entrepreneur Eric Lefkofsky (best known as co-founder of Groupon). Headquartered in Chicago, Tempus was born from Lefkofsky’s personal mission to improve cancer care after his wife’s battle with breast canceren.wikipedia.org. The company’s core focus is on applying AI and data analytics to personalized medicine. Tempus has built what it calls an “operating system” for healthcare: a platform that ingests vast amounts of clinical and molecular data (gene sequences, lab tests, medical records, imaging, etc.) and makes it accessible for treatment decisions and researchinsidermonkey.com. Its goal is to enable doctors and
8 October 2025
···

Stock Market Today

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

7 February 2026
SAP SE closed at 171.22 euros on Xetra Friday, up 0.43%, after disclosing its treasury shares rose above 5% of capital, reaching 61,737,035 shares. The increase follows the launch of a buyback plan worth up to 2.6 billion euros through July 2026. SAP’s U.S. shares finished at $203.34. Investors await SAP’s Integrated Report on Feb. 26 and next results on April 23.
L’Oreal share price slips into weekend as OR.PA heads for annual results test

L’Oreal share price slips into weekend as OR.PA heads for annual results test

7 February 2026
L’Oréal shares closed at 394.05 euros in Paris on Friday, down 0.16%, marking a second straight session of losses. The company will release its 2025 annual results after markets close on Feb. 12, with a financial meeting set for Feb. 13. About 319,000 shares traded Friday in a range between 385.70 and 395.10 euros. The STOXX 600 rose 0.9% to 617.12 points.
Go toTop